Walbert Keliinsider trades

In SEC Form 4 filings, Walbert Keli is listed as Director of Hemab Therapeutics Holdings, Inc. (COAG). Walbert Keli reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Sep 25.

Companies and roles

Company	Role	Transactions	Last filed
COAGHemab Therapeutics Holdings, Inc.	Director	1	Sep 25

Cluster buys

No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).

Form 4 historysince 2026-09-25

Company	Traded	Filed	Type	Shares	Price	Value	Owned after	10b5-1 plan	Filing
COAGHemab Therapeutics Holdings, Inc.	Sep 24	Sep 25	A · derivative	36,000	$35.72	$1,285,920	36,000	No	Form 4

Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.